The lung fibrosis pipeline thins

This month’s “win” for Pliant Therapeutics’ PLN-74809 in idiopathic pulmonary fibrosis did not convince investors, with the group’s stock closing down 1% on September 7. But Pliant is at least still in the race, which is more than can be said for several other erstwhile IPF hopefuls.